Latest

Health and bio · United Kingdom · founded 2021

Isomorphic Labs valuation and IPO status

Isomorphic Labs's latest valuation figure, $50B (17 Nov 2026), comes from reported funding talks, not a priced transaction. IPO status: private.

Source tier: ReportedSource: The Next Web (citing Bloomberg)

Latest valuation$50BBasis: reported talks (not a priced deal)Source tier: ReportedAs of The Next Web (citing Bloomberg)

Information only, not investment advice. Figures are from public sources; tiers show how solid each one is.

About Isomorphic Labs

Alphabet's AI drug-discovery company, spun out of DeepMind and run by Demis Hassabis; no drug is in human trials yet.

Closed a $5B Series C on 17 Nov 2026 led by Greenoaks and Sequoia (company announcement) without disclosing the valuation; Bloomberg reported it was raising at about $50B.

Key investors

Alphabet, Greenoaks, Sequoia Capital, Andreessen Horowitz, Thrive Capital, GV, CapitalG, MGX, Temasek, UK Sovereign AI Fund.

Isomorphic Labs: quick answers

How much is Isomorphic Labs worth?

Isomorphic Labs has no disclosed priced valuation. Reported funding talks put it at $50B (17 Nov 2026), according to The Next Web (citing Bloomberg), so it is not ranked in our tracker. We label it reported.

Is Isomorphic Labs going public?

Status: private.

Who invests in Isomorphic Labs?

Named investors include Alphabet, Greenoaks, Sequoia Capital, Andreessen Horowitz, Thrive Capital, GV, CapitalG, MGX, Temasek, UK Sovereign AI Fund.

Sources

  1. The Next Web (citing Bloomberg). thenextweb.com, Source tier: Reported
  2. Bloomberg. bloomberg.com, Source tier: Reported

Related: OpenEvidence, Neuralink. Valuation tracker, technical valuation.

Alerts

Anthropic IPO alerts by e-mail

Get an e-mail when Anthropic starts trading.